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Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension: experience of 




Balloon pulmonary angioplasty (BPA) has recently been developed as an alternative and less- 
invasive treatment strategy for chronic thromboembolic pulmonary hypertension (CTEPH), but 




To examine the effects of BPA on patients with inoperable disease or residual pulmonary 




From June 2015 to September 2019 we enrolled symptomatic (WHO-FC ≥ II) inoperable CTEPH 
patients and patients with residual PH after PEA. At baseline, immediately before the first BPA 
session and 3-6 months after last BPA session all patients underwent clinical evaluation, six-minute 
walking distance (6MWD) and right heart catheterization (RHC). For comparisons Friedman test 





Forty-seven patients [male 45%, median age 68 (51-74) years, 40 inoperable and 7 with residual PH 
after PEA] were treated for a total of 136 sessions (median number of sessions for each patient: 2); 
during each session we treated 2 (2-3) vessels.  
Results are shown in the Table below.  
Forty-six patients were treated with medical therapy before BPA (18 with combination therapy).  
Five pulmonary artery dissection and 2 hemoptysis with clinical impairment were documented during 
the procedures; 33 patients had lung injury (radiographic opacity with/without hemoptysis and/or 
hypoxemia), 7 patients had access site complications.  
Five patients died during follow-up (none within 30 days from the procedure) because of sepsis (1), 




































WHO-FC III-IV  

























































CI, Cardiac Index; mPAP, mean Pulmonary Arterial Pressure; PVR, Pulmonary Vascular Resistance; PA O2 Sat, 
Pulmonary Artery Oxygen Saturation; RAP, Right Atrial Pressure; 6MWD, 6 Minute Walking Distance; WHO-FC, 
World Health Organization Functional Class; PAC, pulmonary artery compliance. 
 
Kaplan Meier Curves 
 
PEA 171 147 140 131 120 114 
Drug 202 155 141 118 102 81 
None 32 19 16 15 14 9 
BPA 47 35 23 12 2 0 
       
Conclusions 
 
BPA is a safe and effective treatment able to improve symptoms and hemodynamic profile in 










47 35 23 12 2 0gruppi = 6
32 19 16 15 14 9gruppi = 4
202 155 141 118 102 81gruppi = 3
171 147 140 131 120 114gruppi = 2
Number at risk
0 12 24 36 48 60
Follow-up (months)
gruppi = 2 gruppi = 3
gruppi = 4 gruppi = 6
Survival
Pag. 5 di 26 
 
Chronic thromboembolic pulmonary hypertension 
 
Chronic thromboembolic pulmonary hypertension (CTEPH), a rare, potentially life-threatening 
disease of the pulmonary vasculature, is classified within group IV pulmonary hypertension (PH) 1 
and characterized pathologically by organized thromboembolic material and by altered vascular 
remodeling initiated or potentiated by a combination of defective angiogenesis, impaired fibrinolysis 
and endothelial dysfunction 2-4 
Dysfunction and remodeling of pulmonary microvasculature similar to the arteriopathy of pulmonary 
arterial hypertension (PAH) are thought to contribute significantly to the pathology of CTEPH and 
lead to ultimately right ventricular failure 5-6.  
The precise pathogenesis of CTEPH remains unclear but appears to be incited by acute pulmonary 
embolism (PE).7 In published prospective studies with the diagnosis confirmed by right heart 
catheterization (RHC) after at least 3 months of anticoagulations, the incidence of CTEPH after 
symptomatic acute PE is reported to range from 0.4% to 6.2%,8-20 giving a pooled incidence of 3.4% 




Both lung ventilation perfusion scintigraphy (VQ scan) and computed tomographic pulmonary 
angiography (CTPA) are accurate methods for the detection of CTEPH with excellent diagnostic 
efficacy (100% sensitivity, 93.7% specificity and 96.5% accuracy for VQ scan and 96.1%, 95.2% 
and 95.6% respectively, for CTPA) 21. Digital subtraction pulmonary angiography (DSA) had been 
considered the gold standard for characterizing vessel morphology in CTEPH but is being challenged 
by advances in non-invasive modalities.  CTPA (Figure 1) is currently widely used for assessment of 
operability and can also be valuable by evaluating bronchial artery collaterals, lung parenchyma 
(mosaic oligemia with minIP reconstruction, Figure 2) and mediastinum.  Advanced CT technologies 
including dual-energy CT, ECG-gated area detector CT, cone-beam CT and contrast-enhanced 
Magnetic Resonance Pulmonary Angiography are emerging as valuable modalities for detailing the 





ß Figure 1 
 
 




Patients with untreated CTEPH are at high risk of progressive PH, right heart failure and death 22. 
Early diagnosis and treatment by a multidisciplinary team are essential 23-24. Pulmonary 
endarterectomy (PEA) is the gold-standard treatment, it is a potentially curative intervention, which 
in expert centres carries an in-hospital mortality rate <5% and leads hemodynamic and functional 
improvement with good long-term survival 25-26. However, less than 60% of patients with CTEPH 
can undergo PEA, and PH persists or recurs after the procedure in 17–31% of patients 27-28. 
 
For patients who are deemed inoperable or who have persistent or recurrent PH following PEA, 
targeted medical therapies developed for PAH can be given 29. The soluble guanylate cyclase 
stimulator Riociguat and endothelin receptor antagonists (ERA) Macitentan are currently the only 
medical therapy for the treatment of CTEPH that has been shown to improve hemodynamics and 
exercise capacity 29-30. Phosphodiesterase 5 inhibitors (PDE5-I) and prostanoids are not approved for 
this indication, because of a lack of positive randomised study evidence. 
Percutaneous balloon pulmonary angioplasty (BPA) is an emerging option for patients with CTEPH 
who are not eligible for surgery or who have recurrent or persistent PH following PEA. 
In this era of a comprehensive approach to CTEPH, an expert centre should be capable of evaluating 







#: multidisciplinary: PEA surgeon, PH expert, BPA interventionist and radiologist 
¶: treatment assessment may differ depending on the level of expertise 
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Balloon pulmonary angioplasty 
 
History, evolution and evidence 
 
The first study of BPA was published in 2001 by Feinstein 31 in the USA, describing 18 patients with 
inaccessible or “nonsurgical” CTEPH. Reperfusion pulmonary edema (RPE) occurred in 11 patients 
and 30-day mortality was 5.5%. Follow-up (mean 36 months) reported improvements in mean 
pulmonary arterial pressure (mPAP), New York Heart Association (NYHA) functional class and 6-
min walking distance (6MWD), and all vessels previously dilated were patent at angiographic 
reassessment. 
Following Feinstein’s report, BPA was abandoned for some years, mainly because of high 
complication rates. However, more recent reports, mainly from Japan, have revived interest. 
Sugimura 33 performed BPA in 12 patients with distal-type CTEPH stabilized for 1–3 months with 
prostanoids, sildenafil and/or bosentan. Pulmonary hemodynamics were improved, and survival was 
better than for historical controls. Kataoka 32 performed BPA in 29 patients with inoperable CTEPH, 
most of whom had previously been treated with an ERA, PDE-5 inhibitor or prostanoid. Functional 
class, brain natriuretic peptide levels and hemodynamics were improved at follow-up; medication 
was unchanged in most patients. Notably, hemodynamic effects took time to develop after BPA. 
Shortly after these studies were published, Andreassen 34 reported results with BPA for segmental 
and subsegmental pulmonary arteries in 20 patients in Norway with inoperable disease or persistent 
PH after PEA. NYHA functional class and hemodynamic values were significantly improved, but 
periprocedural mortality was 10% and RPE occurred in seven patients. After 51 months’ follow-up, 
85% of patients were still alive. Three further publications from European centres, one in 37 patients 
24 and two others, each in nine patients 39-40, described improvements in mPAP, exercise capacity and 
functional class after BPA, with low rates of complications. 
Several Japanese centres have described improvements in hemodynamics, symptoms and exercise 
capacity after BPA, with generally low rates of major complications and post-procedural mortality 
35- 37, 41-44, 46 with some follow-up over a year 36, 37, 44. 
One report from Japan described outcomes of CTEPH managed using drug therapy (including 
pulmonary vasodilators), BPA or PEA 37. Despite significantly worse hemodynamic parameters at 
baseline, patients managed with interventional therapies (PEA or BPA) had significantly superior 
survival at 5 years than those treated medically (98% versus 64%, respectively; p<0.0001). The 
efficacy and safety of BPA were similar in younger (<65 years) and older (⩾65 years) patients 38. 
Data comparing outcomes of PEA in operable patients with those of BPA in inoperable patients 
suggest that the efficacy and safety of the two procedures are similar in their target cohorts 47. 
In addition to the improvements in hemodynamics and functional capacity, there is accumulating 
evidence that BPA leads to improvements in right ventricular function, including volumes, ejection 
fraction, peak systolic strain, myocardial remodeling and alleviation of dyssynchrony 45, 46, 48-50. 
It is difficult to compare results between countries and regions because of differences in patient 
selection and procedures, and possible differences in vascular structure and function related to 




All patients with pulmonary hypertension, including CTEPH, should be evaluated and managed in a 
centre with specialist expertise and facilities 29, including a CTEPH team 5. A referral centre should 
follow ⩾50 patients per month and receive at least 2 new referrals for PAH or CTEPH each month 
29.  
BPA should be reserved for expert centers (as for PEA) because it is a complex procedure that is not 
risk free and even with the technical refinements, there remains a steep learning curve in order to 
safely, effectively and consistently perform BPA 54. A successful BPA requires extensive training 
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and case experience. BPA patient selection starts with a multidisciplinary review of all available and 
pertinent data and the first consideration in the evaluation of patients for BPA is the feasibility of 
PEA 29. The European Society of Cardiology/European Respiratory Society guidelines 29 state that 
BPA may be considered for patients who are technically inoperable or who carry an unfavourable 
risk/benefit ratio for PEA (class IIb recommendation, level of evidence C).  
This recommendation covers a very heterogeneous group and there are currently no data to identify 
those patients who might benefit most from BPA. Patient groups in whom BPA could potentially be 
used include those with inoperable CTEPH due to distal distribution of vascular obstructions, those 
with an unfavourable risk/benefit ratio for PEA (for example, few lesions but severe hemodynamics, 
or extreme surgical risk because of comorbidities, etc.), patients with persistent/recurrent PH after 
PEA, patients in need of rescue angioplasty after early failure of PEA 51, patients with residual lesions 
after PEA, and patients with inoperable or persistent/recurrent CTEPH and an inadequate response to 
medical therapy. Some patients may have no distinct comorbidities that directly affect the surgical 
risk of PEA, but have limitations (e.g. general frailty, severe chronic obstructive pulmonary disease 
or inability to walk) such that the potential functional gain from surgery is very small (“low benefit” 
rather than “high risk”). BPA may be appropriate in these patients and is within the guideline 
recommendation. Conversely, BPA should not be offered to patients with large central clots or 
unilateral total occlusion 68 but can sometimes be justified as a rescue procedure for some 
compromised patients that can be subjected to PEA but with severe comorbidities that contraindicate 
the surgery 62-63. 
The rationale is to open obstructed vessels or widen stenotic lesions using a catheter-based 
intervention rather than the invasive surgery of PEA. The intention is to improve hemodynamics and 
pulmonary perfusion, ultimately reducing right ventricular afterload and preventing right ventricular 
failure.  
Anatomical and functional assessment of pulmonary arteries and lung perfusion are critical to identify 
the target vessels 42. A selective pulmonary angiogram of the target vessels will show more details 
and serves as confirmation prior to intervention during BPA but may not capture all the distal lesions 
potentially amenable to BPA, necessitating multiple complementary imaging modalities such as 
intravascular imaging and pressure gradient analysis to aid in lesion assessment and balloon sizing 
40. 
After identification of pulmonary artery lesions that can be treated a guide wire across the lesion or 
occlusion and balloon dilatation lead to restore pulmonary blood flow. Staged procedures with repeat 
catheterisations and dilatations are needed to achieve optimal hemodynamic results.  
A comparison in terms of efficacy and complications between PEA and BPA is almost impossible: 
the two techniques are not mutually alternative 56. Instead the hybrid approach between the two 
methods could be consider a treatment option for selected cases those who have a proximal 




Percutaneous vascular access for BPA is femoral or jugular vein, using long sheaths through which 
pre-shaped guiding catheters (e.g. multipurpose shape, right or left coronary Judkins or left Amplatz 
shape) are inserted. 
A long 6-, 7- or 8-French sheath containing a pre-shaped 6-French guiding catheter is placed in the 
pulmonary trunk and guided to the right or left main pulmonary artery. Usually the primary target for 
BPA (as for PEA) is the right lower lobe, because of its size and physiologically greater compartment 
of blood flow 52. In patients with low mPAP (i.e. <40 mmHg), more than one lobe may be treated in 
a single session 32, 33, 53, 54. 
It is important to have information about peripheral branches distal to the lesion in order to perform 
BPA safely 52. In severe cases, the primary goal is to reduce pressure by addressing simpler lesions 
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first (i.e. web lesions or ring-like stenoses). The guide wire is passed carefully across the target lesion: 





Recent practice in Japan has employed pressure wires to measure the ratio of distal to proximal 
pressures across the target lesion: this information can be used to reduce the risk of RPE 36, 53. In some 
cases, soft hydrophilic guide wires are used, e.g. for the management of occlusive pulmonary artery 
lesions. 
To begin the procedure, wires with tip loads <1 g should be used. Balloons should be undersized (i.e. 
a low balloon/artery ratio) to reduce the risk of vessel injury and reperfusion edema: a 2-mm balloon 
is typically used for initial dilatation, followed by larger balloons according to lesion size and residual 
pressure. The balloon is inflated by hand until the fluoroscopic waist disappears or until the balloon 
is expanded at 5–8 atm. For that reason, compliant balloons are preferred. Repeat dilatations with 
bigger balloons are performed if there is <50% increase in angiographic vessel size and an increase 
of pulmonary venous backflow is documented. In case of chronic total occlusions, microcatheters 
and wires with higher tip loads are used, similar to conventional chronic total occlusion techniques. 
 
Between three and 10 sessions of BPA are usually required for each patient to achieve the desired 
mPAP reduction and treat all amenable lesions. The number of sessions required depends on the 
extent of disease, the location and configuration of the lesions and the skills of the operator. 
At each session, treatment is targeted to segmental and subsegmental pulmonary arteries of one 
pulmonary lobe. The need for repeated sessions is an important consideration when explaining the 
procedure, planning resources and evaluating potential hazards from repeated exposure to radiation 
and contrast media, including contrast-induced nephropathy.  
After BPA, many patients still show elevated pressure and resistance values 24: hybrid therapy 
(medical treatment combined with BPA) may be a promising option 24. This could include acute or 
chronic “bridging” treatment before BPA, to improve hemodynamics and potentially reduce the risk 
of complications, or after BPA in patients whose hemodynamic response is unsatisfactory. 
Prospective studies need to be performed in this setting. In many BPA studies, some or all patients 
received additional targeted medical therapy to stabilize the patient or improve hemodynamics before 
the procedure, and this therapy was generally continued afterwards. However, medical therapy in 
conjunction with BPA has not been systematically evaluated and currently no robust data exist on the 
benefits of medical treatment before and after BPA. 
 




In retrospective study it was found that different types of lesions correspond to different effects and 
a variable incidence of complications. For this reason it was necessary to create a new classification 
that took into account the angiographic aspect of pre-treatment lesions 42. Five categories have been 
identified based on the lesion opacity and the blood flow distal to the lesion (figures below): 
 
A) ring stenosis 
B) web 
C) sub-occlusive lesions 
D) total vascular occlusions 
E) tortuous lesions 
 
 
Ring stenoses and "webs" have the highest success rate and the least chance of causing complications 
42. Despite the availability of different imaging techniques, the use of more advanced methods make 
BPA a long, complex and expensive procedure, as well as impossible to implement in patients with 
a more compromised clinical status. Therefore, to standardize the procedure, it is necessary to identify 





Results demonstrating the impact of BPA on right ventricular function (analyzed both by 
echocardiogram and cardiac MRI) come from retrospective studies. There is a "reverse remodeling" 
of the right ventricular associated with an overall improvement of the hemodynamic parameters 48. 
Cardiac MRI 3-6 months after the last session documents reduction of right ventricle dimension and 
thickening, increase of ejection fraction and an improvement in the straightening of the 
interventricular septum 35. Reduction in right ventricular dyssynchrony, recovery of left ventricular 
function following decompression by the right ventricle and reduction of resting heart rate are also 
described as an effects of BPA 49-50.  
BPA also has a beneficial effect in terms of ventilatory function: with the cardiopulmonary exercise 
test carried out immediately after the last procedure, the maximum oxygen consumption is 
significantly improved. It is interesting to note that it correlates more with the number of procedures 
performed than with the hemodynamic parameters: probably because, besides hemodynamics, BPA 
also produces a beneficial effect on the symptoms of heart failure and, consequently, induces a 
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peripheral adaptation between one session and the other 58. Furthermore, the reduction of 
intrapulmonary shunts and the parallel increase in venous saturation of oxygen contribute to 
improving hypoxemia. 
At the systemic level, improvements in renal function, metabolism, nutritional status and vascular 
function have been described 59. In particular, despite the use of iodinated contrast agents during the 
procedure, renal function is improved for two main reasons: first, BPA leads to a reduction in venous 
congestion, a major cause of worsening of renal function in patients with heart failure; second, the 
increase in cardiac output improves pre-renal component 64.  
Although based on individual questionnaires, recent studies show that BPA also has a significant 




Different categories of complications were identified: 
During the procedure: 
§ Vascular injury with/without haemoptysis  
§ Wire perforation  
§ Balloon overdilatation  
§ High-pressure contrast injection  
§ Vascular dissection  
§ Allergic reaction to contrast  
§ Adverse reaction to conscious sedation/local anaesthesia  
After the procedure: 
§ Lung injury (radiographic opacity with/without haemoptysis, with/without hypoxaemia)  
§ Renal dysfunction 
§ Access site problems 
 
Vascular injury and dissection can lead to signs and symptoms such as haemoptysis, coughing or 
hypoxia within 20 min, although they can be asymptomatic in some cases.  
Wire perforation is the most common pulmonary artery injury and is usually caused by deep insertion 
of a guide wire into peripheral small branches, although if managed correctly. Wire perforation can 
be reduced by stabilizing the guiding catheter and avoiding deep insertion of the guide wire in lesions 
with unclear distality. The risk may also be reduced by avoiding BPA for complete obstructions, 
which require a heavy-weight-tip wire. 
Balloon overdilatation and high-pressure contrast injection can lead to the rupture of a pulmonary 
arterial branch with a blood extravasation that is manifested by hemoptysis and worsening of 
oxygenation; over time, heart failure and shock may occur. The first method of intervention involves 
the use of a balloon at low pressure upstream of the breaking point for about 15 minutes. The 
procedure can be repeated several times and, if it does not lead to the resolution, an option is 
embolization with bioabsorbable gel or with metal spirals, which exclude the vessel irreversibly. 
Finally, although there are few data available on their long-term effectiveness 60, it may be necessary 
to insert coated stents. Sometimes, to stop bleeding, it may be appropriate to evaluate the surgeon's 
intervention. 
Damage caused by adhesion of the guides or catheter to the vascular wall may cause a pulmonary 
artery dissection. A close follow-up showed that, if left untreated, the dissection tends to disappear 
generally in one week 61. 
The RPE represents the most frequent complication and was observed by Feinstein in 2/3 of the 
patients. Reperfusion edema / alveolar hemorrhage develops 24-72 hours (Figure 4) from the 
procedure for a number of factors: microtraumas caused by the guides, release of inflammatory 
mediators and due to the hemodynamic effect caused by high-pressure reperfusion of areas that for a 
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long period received little amount or zero blood flow 52. Following the introduction of IVUS (led to 
a more precise selection of the target segment and of the balloon size), the clinical-instrumental 
follow-up of patients undergoing BPA showed a clear reduction in severe lung injury, to the detriment 





BPA is associated with a higher incidence of RPE compared to PEA. The reason is the fractionation 
of BPA treatment in several session: each distal pulmonary arterial branch mechanical opened 
receives a high pressure flow coming from the healthy district upstream; in PEA, most of the 
obstructions are removed in a single session, so the flow is redistribute in the pulmonary arterial tree 
downstream. Furthermore, the effect of pro-inflammatory cytokines seems to have an indirect role. 
Despite various efforts to reduce its incidence, the complication seems to be inevitable, especially 
following the first sessions. Therefore the focus has shifted to prevention: PEPSI (Pulmonary Edema 
Predictive Scoring Index) was created 52, obtained by multiplying the variation of the Pulmonary 
Flow Grade score by the baseline value of pulmonary vascular resistance (PVR). This index has an 
high negative predictive value and correlates most with the risk of RPE. Pulmonary Flow Grade is a 
score based on the corresponding TIMI (Thrombolysis in Myocardial Infarction), used for the 
coronary angioplasty procedure. It divides the perfusion of the target vessels into four levels based 
on their angiographic appearance:  
• Grade 0: absence of anterograde flow in the pulmonary arterial branches or minimal passage of 
contrast medium that remains trapped, with lack of opacification of the distal vascular bed.  
• Grade 1: partial perfusion of the pulmonary arterial branches with passage of contrast medium in 
the circulation downstream of the lesion.  
• Grade 2: complete perfusion of the distal pulmonary arterial branches with partial perfusion of the 
pulmonary venous branches, in which the flow appears slower compared to the areas not affected by 
obstruction. 
• Grade 3: complete perfusion of arterial and pulmonary venous branches.  
The treatment of a target lesion should lead to the achievement of grade 3: the grade improvement is 
significantly related to hemodynamic improvement. Furthermore, taking into account the basal PVR, 
PEPSI could play a role in defining the subgroup of patients candidates to benefit from a more 
aggressive approach, treating more vessels for each session: the therapeutic effect of BPA, in fact, is 
directly proportional to the number of treated vessels 53. 
Since the development of RPE correlates with basal values of mean pulmonary arterial pressure, 
Inami et al. introduce pressure-wire guides capable of accurately detecting pressure values upstream 
and downstream of the target lesion. This reduces the reperfusion damage monitoring directly the 
blood pressure values and contributes to obtaining a significant hemodynamic improvement, 
minimizing the number of insufficiently treated vessels 36. 






In CTEPH, stenoses or obstructions of the pulmonary arteries due to unresolved organized thrombi 
cause an elevation of pulmonary pressure and PVR, which can result to progressive right heart failure 
1-2. Traditionally, the treatment of choice for CTEPH is PEA 3-4; however, not all patients are eligible 
for PEA and more than 30% of patients with CTEPH are deemed unsuitable due to distal lesion, 
advanced age, or comorbidities and have a poor prognosis and limited treatment options. 
Furthermore, of those who have undergone the surgery, 17%–31% experience recurrence or 
persistence of PH 5-6. 
Recently, BPA has arisen as a promising alternative treatment strategy for CTEPH patients with 
inoperability or recurrence of PH after PEA: previous studies from Japan and Europe showed 
favorable results with regard to hemodynamics 7-8, right ventricular function and exercise capacity 9-
11, quality of life 12 and respiratory function13 in CTEPH patients after BPA and risk/benefit imbalance 
appear to be safe in experimented centres.  
There have been no prior studies on the efficacy and safety of BPA in CTEPH patients from Italy. 
Therefore, we sought to compare clinical and hemodynamic parameters at the baseline and last BPA 
session in CTEPH patients who were inoperable or who experienced recurrence or persistent PH after 




The aim of this study was to compare clinical and hemodynamic parameters at the baseline and after 







The present study was single center, observational study of CTEPH patients who received BPA 
between June 2015 and September 2019 at Sant’Orsola Malpighi Hospital of Bologna. 
All symptomatic patients (NYHA ≥ II), incident or prevalent, with inoperable CTEPH or with 
residual PH post PEA with a hemodynamic profile characterized by mPAP > 25 mmHg and PVR > 
3.0 WU at the time of evaluation were considered eligible for BPA.  
Baseline assessment included the NYHA functional class, 6-minute walk distance (6MWD), high 
resolution chest CT (HRCT), hemodynamic parameters by right heart catheterization (RHC) and non 
selective pulmonary angiography. 
For this study we collected clinical and hemodynamic parameters in three different moments of the 
clinical history of our patients: at baseline (for inoperable patients we consider baseline RHC and for 
operable patients that underwent PEA we consider the first RHC post PEA that show residual PH), 
immediately before the first BPA session and after 3-6 months after the last BPA session; in patients 
who have not yet completed the treatment (target goals not yet been reached) and therefore have not 
performed a reassessment after the end of BPA program, we consider as post-BPA data the last RHC, 
6MWD and functional evaluation performed immediately before the last session. 
The day after every session HRCT is performed to identify "clinically silent" adverse events 








All patients undergoing BPA receive written information regarding the procedure and provided 
informed consent. The BPA procedure is carried out by at least two interventional cardiologists.  
Oral anticoagulation (OAC) with vitamin K antagonist is withdrawn at least 3 days before the 
procedures and replaced with low weight molecular heparin, while patients treated with Non-vitamin 
K antagonist oral anticoagulants withdrawn OAC one or two days before the procedure (according to 
the number of administrations of the drug). 
Firstly, we placed a 7F indwelling sheath into a mainly femoral vein and a 6F long sheath was brought 
into the main pulmonary artery. We performed RHC and then selected a branch of the pulmonary 
artery using an appropriate 6F guiding catheter and performing selective angiography to detect target 
lesions: the choice was optimized by the possibility of using bi-plane angiographic room in 







Unfractionated heparin was additionally infused after introduction of the guiding catheter according 
to the activated clotting time (target during procedure: 200-300). A 0.014-inch wire crossed to the 
targeted lesion, and then the lesion was dilated using balloon catheters of the appropriate size. The 
balloon was inflated by hand until the indentation disappeared or until the balloon is fully expanded. 
If the vessel was dilated for the first time, a small-sized balloon was used regardless of reference 
diameter of the segmental artery to prevent procedure related complications and a slightly bigger 
balloon was used subsequently (or in the subsequent session). After inflation, angiography was 
performed to confirm sufficient dilation and the presence of ruptured vessels. Dilatation was repeated 
if deemed insufficient.  
The day after BPA each patient underwent high resolution chest CT, irrespective of the clinical events 
that occurred during the session, to detects “silent” side effects and to manage the resumption of 
OAC. 
A second session of BPA was done within 30-60 days of the first BPA session. We performed 
additional sessions of BPA if patients were still symptomatic (NYHA more than II) or had a mean 








Data, including number of sessions and vessels treated, are expressed as median and interquartile 
range. Comparisons between baseline, pre-BPA and post-BPA data were conducted with Friedman 
test with two-by-two comparison and the pairwise post hoc analysis was performed with Bonferroni 
correction. Survival was calculated starting from the catheterization performed before the first BPA 
session and for the survival analysis we used the Kaplan-Meier method, considering mortality for all 
causes and comparing BPA group with other group according to different therapeutic strategies [PEA, 




47 patients with CTEPH [40 with inoperable disease (85%) and 7 with PH residual/recurrence after 
PEA (15%)] were considered eligible for BPA treatment; male 45%, median age 68 (51-74) years. 





































CI, Cardiac Index; mPAP, mean Pulmonary Arterial Pressure; PVR, Pulmonary Vascular Resistance; PA O2 Sat, 
Pulmonary Artery Oxygen Saturation; RAP, Right Atrial Pressure; 6MWD, 6 Minute Walking Distance; WHO-FC, 
World Health Organization Functional Class; PAC, pulmonary artery compliance. *40 patients 
 
At baseline current PAH specific therapies and anticoagulation strategy were: 
PAH specific therapy N (%) 
None 34 (72%) 
MonoTx 8 (17%) 
Combination Tx 5 (11%)* 
*One in triple combination therapy with iv epoprostenol 
 
 
Anticoagulation drug N (%) 
Warfarin 28 (60%) 
NOACs 17 (36%) 
Heparin 2 (4%) 
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Baseline assessments were conducted approximately 6 months (2-42) before the observation period; 
the reason for this extended range of time is that we included in BPA program both incident and 
prevalent patients (who were followed in Bologna Center and perform first RHC since before June 
2015 and meet criteria for our study). 
 
The medical therapy at the time of insertion in the study were: 
 
PAH specific therapy N (%) 
None 1 (2%) 
MonoTx 28 (60%) 
Combination Tx 18 (38%)* 
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The following table shows changes from baseline to pre-BPA: 
 
N° 47 patients Baseline Pre-BPA p 
NYHA III-IV 



















































During the study period 136 sessions of BPA were performed and each patient went through an 
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At the end of the observation period 42 patients (89.4%) performed at least a post-BPA clinical, 
functional and hemodynamic evaluation [time 11 (5-19) months after the pre-BPA assessment]. 
5 patients did not perform a reassessment of the clinical and hemodynamic picture for the following 
reasons: 
• A lung lesion compatible with heteroplasia was found in 1 patient after the first BPA session. 
For this reason, the BPA program has been suspended. 
• 1 patient delayed the hemodynamic evaluation after first BPA session because, in the 
meantime, he underwent coronary angioplasty due to acute coronary syndrome and then he 
died for sudden death during follow up before the post-BPA revaluation. 
• 1 patient died for sepsis before the post-BPA revaluation 
• 1 patient performed the first BPA session near the end of the observation period. For this 
reason, it was not possible to have a revaluation. 
• 1 patient refused to perform any other invasive test after the first session of BPA 
 
There was no modification of PAH specific drugs between pre-BPA and the end of the observation 
period 
 
Clinical, functional and hemodynamics effects of BPA are shown in the following table: 
 
N° 42 patients Pre-BPA Post-BPA p 
NYHA III-IV 



















































Treatment goals (mPAP <30 mmHg and/or PVR <4 WU) was reached within the study period for 18 
(38%) patients. The other patients have been scheduled for additional BPAs in the near future except 
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CI, Cardiac Index; mPAP, mean Pulmonary Arterial Pressure; PVR, Pulmonary Vascular Resistance; PA O2 
Sat, Pulmonary Artery Oxygen Saturation; RAP, Right Atrial Pressure; 6MWD, 6 Minute Walking Distance; 




During the observation period 44% of the sessions took place in the absence of clinical and/or 
radiological complications. The remaining 56% of the sessions were characterized by events for the 
most of the times mild and with spontaneous remission, which rarely required an active role by the 
medical-nursing staff. 
All the clinical-radiological events occurring in the peri-procedural period were grouped into four 
main categories: hemoptysis, reperfusion edema/alveolar hemorrhage, pulmonary vascular 
dissections and complications at the level of vascular accesses. 
Hemoptysis was the most frequent clinical complication, affecting 14 patients (30%) for a total of 24 
procedures (18%). In most cases (92%) it resolved spontaneously as it was a mild hemoptysis / 
haemoftoe in the absence of significant desaturation or hemodynamic compromise; a case of 
moderate hemoptysis required administration e.v. of protamine, while in only one case the severity 
of the complication was such as to require, in addition to the recombination by protamine infusion, 
endotracheal intubation and subsequent admission to intensive care unit. No patient required 
percutaneous cardiopulmonary support. 
As already illustrated above, in order to highlight aspects of RPE or alveolar hemorrhage, all patients 
(even in the absence of clinical events) underwent HRCT scan 24 hours after each single session. 
Overall, the radiological evidence of RPE involved 33 patients (70%) for a total of 80 sessions (59%).  
Complications at the level of vascular accesses following the execution of right cardiac 
catheterization by right femoral venous were documented in 7 patients (15%) with a total of 7 
procedures (5%): in particular, we recorded four hematoma (two of them supplied from the superficial 
femoral artery), two arteriovenous fistula and a pseudoaneurysm. 
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Pulmonary artery dissection/perforation was documented in five patients (11%), only one episode led 
to hemoptysis, desaturation and required direct medical intervention (use of a balloon at low pressure 
upstream of the breaking point); the other four remained a “silent” side effect because were observed 
at fluoroscopy during selective angiography of treated vessel at proximal level and did not correlate 
to any symptom or clinical event.  
None of the patients required an extracorporeal membrane oxygenation. 
 
The following table resume the complication rate: 
 
 N° patients (%) N° sessions (%) 
Hemoptysis 14 (30) 24 (18) 
RPE 33 (70) 80 (59) 
Vascular access complication 7 (15) 7 (5) 




During the follow-up 5 deaths were recorded: one patient for sepsis, one for heart failure, one for 
arrhythmic storm, one had an advanced cancer problem and one patient with known severe 
multivessel coronary artery disease died of sudden cardiac death; during BPA sessions and in the 
following 30 days no deaths (0%) occurred, given that it goes to confirm the safety of this procedure. 
 
Kaplan Meier Curves 
 
 
PEA 171 147 140 131 120 114 
Drug 202 155 141 118 102 81 
None 32 19 16 15 14 9 

















47 35 23 12 2 0gruppi = 6
32 19 16 15 14 9gruppi = 4
55 41 102 81gruppi = 3
47 40 120 1 4gruppi = 2
Number at risk
0 12 24 36 48 60
Follow-up (months)
gruppi = 2 gruppi = 3
gruppi = 4 gruppi = 6
Survival




For CTEPH there are several therapeutic strategies, each of which is dedicated to selected patient. 
Surgical treatment, when possible, must be considered the gold standard, as it is potentially curative, 
and the long-term survival of the operated subjects is significantly higher than that of the non-
operated subjects 66. The hemodynamic effects are immediate with a sudden drop in pulmonary 
pressures. Therefore, the careful selection of operable patients remains fundamental, which starts 
from the diagnosis of CTEPH. 
Despite the many advances in recent years, the high percentage of inoperable patients or those with 
residual PH after surgery 27 requires effective and safe alternative treatments: precisely for these 
patients over the last few years, BPA has been emerging, an interventional method aimed at the 
unblocking of pulmonary arterial vessels that are affected by distal location of thromboembolic 
material. This method is still limited to a few expert centres at international level and in the process 
of optimization, both for long-term effectiveness and safety. 
The aim of our study was to demonstrate efficacy and safety of BPA procedure in patients with 
inoperable CTEPH or with residual PH post PEA referred to Sant’Orsola-Malpighi Hospital of 
Bologna. 
Our centre started in June 2015 the selection of patients to be submitted to BPA with a multi-step 
program of dilation sessions with the final goal of reaching mPAP values <30 mmHg and RAP <4.0 
WU. 
47 patients eligible for percutaneous treatment were identified: at the time of enrollment in the study, 
a part of the patients had already been followed at the PH center of this Hospital and was being treated 
with PAH specific therapy. Each patient was reassessed from a clinical, functional and hemodynamic 
point of view before underwent a percutaneous treatment. Comparing the baseline data obtained at 
the first evaluation in Bologna centre and those obtained before the first BPA session [distance 6 
months (2-42)] we observed that medical therapy ("reverse remodeling" of distal open pulmonary 
circulation not involved in thromboembolic processes) determined the stabilization of symptoms, 
exercise capacity and main hemodynamic parameters. 
At the end of the observation period 42 patients (89.4%) performed at least a post-BPA clinical, 
functional and hemodynamic evaluation [time 11 (5-19) months after the pre-BPA assessment]; after 
a total of 136 sessions [2 sessions (2-3) per patient] we documented a decrease in mPAP from 43 (36-
48) to 35 (29-40) mmHg equal to 19 % (p- value <0.05), a reduction in PVR from 7.2 (4.8-9.9) to 4.7 
(3.3-6.3) WU equal to 35% (p value < 0.05) and an increase in IC from 2.7 (2.2-3.0) to 2.9 (2.4-3.5) 
l/min/m2 equal to 7% (p value <0.05). Along with hemodynamic changes also exercise capacity had 
improved, with an increase in distance at 6MWD of 21 meters, from 425 (344-493) to 446 (373-539) 
meters (p value <0.05). We also observed a reduction in the number of patients in NYHA class III-
IV from 83% to 42% (p value <0.05). 
Regarding the safety profile, we considered both clinical and "silent" events by performing HRCT 
scan 24 hours after each BPA session. During the 136 BPA sessions there were 24 episodes of 
hemoptysis (involving 14 patients) which still represents the most frequent peri-operative 
complication that occurred in our centre, although in most cases it is mild (in one case, protamine 
infusion was required to stop the bleeding and in another case it was also necessary endotracheal 
intubation); the event may be an expression of direct vascular damage or due to reperfusion. 
We have documented five episodes of iatrogenic dissection/perforation of a segmental pulmonary 
artery (4% of the total number of sessions): only one of that was related to clinical and hemodynamic 
repercussions and require direct treatment. 
From the radiological point of view, however, we have highlighted the appearance of reperfusion 
edema/alveolar hemorrhage in 59% of the sessions; radiological change has also been interpreted as 
an indication of successful reperfusion and not only as a complication. Data provided by the HRCT 
scan were useful also for management of anticoagulant therapy immediately after the procedure. 
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From our experience, pulmonary angioplasty has proved to be an effective and safe procedure in 
patients with CTEPH who were deemed inoperable due to distal localization of the thromboembolic 
material or with residual PH post PEA, constituting a therapeutic option preferable to 
pharmacological therapy alone. 
Comparing the patients of the study with the historical data present in our register relating to CTEPH 
patients not subjected to this treatment, although observing a peri-procedural mortality rate of zero in 
the short term, it is not possible to define a clear advantage on survival in the absence of consistent 
long-term data. 
Other relevant limitation of this study is that the results obtained are negatively affected by many 





The current knowledge of CTEPH leads us to consider this condition as a complex disease comprising 
proximal or distal (or both) chronic obstruction by organized fibrotic thrombus emboli, small vessel 
disease and remodeling of the whole pulmonary vascular bed. Even if the gold standard treatment for 
this disease remain PEA, BPA has emerged as a promising safe and effective procedure in 
experienced hands, able to improve symptoms, exercise tolerance and hemodynamic profile for 
inoperable patients and for patients with residual PH after surgery. 
An expert centre must be able to offer a multimodal, individualized approach to treatment integrating 
surgical, interventional, imaging and medical PH expertise with the development of clear outcomes 
analyses. Until now Sant’Orsola-Malpighi Hospital of Bologna is the only Italian centre able to offer 
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